In silico analysis identified hydroxyxanthone derivatives as dual inhibitors for colorectal cancer, indicating future potential therapies.
Hydroxyxanthone derivatives X4, X5, and X7 exhibit the strongest potential as dual CDK2/EGFR inhibitors and may, therefore, serve as promising candidates for colorectal cancer therapy. Nevertheless, further in vitro and in vivo investigations are required to experimentally validate their therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Hermawan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: